This product is for research use only, not for human use. We do not sell to patients.
Size | Price | Stock |
---|---|---|
500mg | $400 | In Stock |
1g | $645 | In Stock |
5g | $1630 | In Stock |
Cat #: V1867 CAS #: 144875-48-9 Purity ≥ 98%
Description: Resiquimod (formerly known as R-848; S-28463; VML-600; R848, S27609) is a potent imidazoquinolinamine-based immune response modifier that acts as an agonist of the TLR 7/8 receptors (Toll-like receptor 7/8) with antiviral and antitumour activity.
Publications Citing InvivoChem Products
Product Promise
- Physicochemical and Storage Information
- Protocol
- Related Biological Data
- Stock Solution Preparation
- Quality Control Documentation
Molecular Weight (MW) | 314.38 |
---|---|
Molecular Formula | C17H22N4O2 |
CAS No. | 144875-48-9 |
Storage | -20℃ for 3 years in powder formr |
-80℃ for 2 years in solvent | |
Solubility In Vitro | DMSO: 63 mg/mL (200.4 mM)r |
Water: <1 mg/mLr | |
Ethanol: 21 mg/mL (66.8 mM) | |
SMILES Code | CC(O)(C)CN1C(COCC)=NC2=C1C3=CC=CC=C3N=C2N |
Synonyms | R-848; S-28463; VML600; R848; S 28463; VML 600; R 848; S28463; VML-600. |
Protocol | In Vitro | Among the TLRs tested (TLR2, 3, 4, 5, 7, 8, and 9), Motolimod (VTX-2337) selectively activates TLR8. Motolimod stimulates the production of both TNFα (EC50=140±30 nM based on 10 donors) and IL-12 (EC50=120±30 nM based on 10 donors) in PBMCs. The EC50 value for MIP-1β induction is 60 nM for Motolimod. |
---|---|---|
In Vivo | Monkeys receive a subcutaneous injection of Motolimod (1 or 10 mg/kg), and plasma is collected predose, 6, 12, 24, and 96 h post-injection. For the 10 mg/kg dose, mean plasma levels of IL-1β increase from baseline levels of 0.5 pg/mL, up to 9.12±2.7 ng/mL (p<0.05, t-test) at 6 h post-administration of Motolimod (10 mg/kg). Circulating levels of IL-18 also increase from a baseline of ~ 1 pg/mL to 68.7±4.4 pg/mL (p<0.05, t-test) at 6 h in response to the Motolimod (VTX-2337) treatment (10 mg/kg). Levels of IL-6 are monitored, as this mediator is induced in response to TLR8 activation, but the release is independent of NLRP3 inflammasome activation. In addition, plasma levels of IFNγ are assessed as a measure of NK cell activation in response to Motolimod treatment. |
Solvent volume to be added | Mass (the weight of a compound) | |||
---|---|---|---|---|
Mother liquor concentration | 1mg | 5mg | 10mg | 20mg |
1mM | 3.1809 mL | 15.9043 mL | 31.8086 mL | 63.6173 mL |
5mM | 0.6362 mL | 3.1809 mL | 6.3617 mL | 12.7235 mL |
10mM | 0.3181 mL | 1.5904 mL | 3.1809 mL | 6.3617 mL |
20mM | 0.1590 mL | 0.7952 mL | 1.5904 mL | 3.1809 mL |
This equation is commonly abbreviated as: C1 V1 = C2 V2
- (1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
- (2) Be sure to add the solvent(s) in order.